Laverock Therapeutics Expands to Tribeca London’s Apex Lab Space

London Bioscience Innovation Centre (LBIC) has announced the expansion of its state-of-the-art facilities within the Tribeca London development, welcoming Laverock Therapeutics. This strategic move into the Apex Building not only provides Laverock with a high-quality research environment but also highlights London’s growing reputation as a preeminent hub for bioscience innovation.

Laverock Therapeutics, known for its cutting-edge gene silencing technology, has strategically chosen the Apex facility for its proximity to world-class academic and translational centres. The decision was influenced by access to a rich talent pool and the vibrant biotech community within London’s Knowledge Quarter. Occupying the first of four buildings in the Tribeca development, Laverock is positioned at the core of London’s largest life sciences project, featuring 600,000 sq ft of state-of-the-art lab space. This move is set to accelerate Laverock’s development of advanced therapies targeting major diseases. The facility’s sustainable design and commitment to Net-Zero Carbon further align with Laverock’s values, offering an environmentally responsible and innovative research environment.

With Laverock Therapeutics establishing its long-term base at LBIC’s new Apex lab space, London’s standing as a global biotech hub is further solidified. This collaboration exemplifies the synergy of state-of-the-art facilities and cutting-edge science, reinforcing Tribeca London as a beacon for innovation in the life sciences industry.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact James Higgins today!